Please use this identifier to cite or link to this item:
https://doi.org/10.3109/08982104.2010.545070
Title: | Development of stealth liposome coencapsulating doxorubicin and fluoxetine | Authors: | Ong, J.C.-L. Sun, F. Chan, E. |
Keywords: | Doxorubicin Fluoxetine Multidrug resistance Remote loading Stealth liposomes Synergism |
Issue Date: | Dec-2011 | Citation: | Ong, J.C.-L., Sun, F., Chan, E. (2011-12). Development of stealth liposome coencapsulating doxorubicin and fluoxetine. Journal of Liposome Research 21 (4) : 261-271. ScholarBank@NUS Repository. https://doi.org/10.3109/08982104.2010.545070 | Abstract: | Stealth liposomes form an important subset of liposomes, demonstrating prolonged circulation half-life and improved safety in vivo. Caelyx® (liposomal doxorubicin; Merck & Co., Whitehouse Station, New Jersey, USA) is a successful example of the application of stealth liposomes in anticancer treatment. However, multidrug resistance (MDR) to chemotherapy still remains a critical problem, accounting for more than 90% of treatment failure in patients with advanced cancer. To circumvent MDR, fluoxetine and doxorubicin were tested in combination for synergistic activity in MCF-7 (human breast carcinoma) and MCF-7/adr (doxorubicin-resistant human breast carcinoma) cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell-viability assay. Coencapsulation of doxorubicin and fluoxetine, using an ammonium sulphate gradient, was investigated, and a factorial experiment was designed to determine the optimal drug-to-lipid (D/L) ratio for coencapsulation. Drug release from Dox-Flu-SL (stealth liposome coencapsulating doxorubicin and fluoxetine) under both in vitro and in vivo conditions was determined. In MCF-7 cells, synergism was demonstrated at specific doxorubicin:fluoxetine ratios of between 0.09 and 0.5 (molar ratio), while MCF/7/adr cells demonstrated synergism across all drug ratios. Coencapsulation of doxorubicin and fluoxetine (Dox-Flu-SL) was successfully achieved (optimal doxorubicin:fluoxetine:lipid molar ratio of 0.02:0.05:1), obtaining a mean concentration of 257±12.1 and 513±29.3 M for doxorubicin and fluoxetine, respectively. Most important, Dox-Flu-SL demonstrated drug release in synergistic ratios in cell-culture media, accounting for the improved cytotoxicity of Dox-Flu-SL over liposomal doxorubicin (LD) in both MCF-7 and MCF-7/adr cells. Pharmacokinetic studies also revealed that Dox-Flu-SL effectively prolonged drug-circulation time and reduced tissue biodistribution. Dox-Flu-SL presents a promising anticancer formulation, capable of effective reversal of drug resistance, and may constitute a novel approach for cancer therapy. © 2011 Informa Healthcare USA, Inc. | Source Title: | Journal of Liposome Research | URI: | http://scholarbank.nus.edu.sg/handle/10635/108333 | ISSN: | 08982104 | DOI: | 10.3109/08982104.2010.545070 |
Appears in Collections: | Staff Publications |
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.